Newron Pharmaceuticals - Evenamide notches up another win (study 008A)
Newron Pharmaceuticals has shared positive top-line data for its evenamide programme from its potentially pivotal Phase II/III trial (study 008A)...
127 Views
Newron Pharmaceuticals - Evenamide set for a pivotal year
Newron Pharmaceuticals has reported results for FY23, an active period for its lead asset, evenamide, being developed for treatment-resistant...
311 Views
Newron Pharmaceuticals - Operational flexibility with new/updated financing
Newron Pharmaceuticals has announced new arrangements that offer the company improved operational flexibility. We estimate a pro forma gross cash...
392 Views
Newron Pharmaceuticals - TRS data green-lights evenamide Phase III plans
Newron has announced positive 12-month data from its Phase II extension trial (study 015) assessing evenamide in 161 patients with...
411 Views
Newron Pharmaceuticals - Key Evenamide readouts on the horizon
Newron is a Swiss Stock Exchange SIX-listed (NWRN) biopharmaceutical company focused on developing novel medicines for diseases of the central...
249 Views